Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Conditions:   Bilateral Breast Carcinoma;   Breast Carcinoma;   HER2/Neu Negative;   Mastectomy Patient;   Recurrent Breast Carcinoma;   Triple-Negative Breast Carcinoma Interventions:   Drug: ATR Kinase Inhibitor M6620;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials